Revance Therapeutics, Inc.
BOTULINUM TOXIN AND THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT

Last updated:

Abstract:

The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.

Status:
Application
Type:

Utility

Filling date:

19 Apr 2021

Issue date:

7 Oct 2021